Related Experiment Videos
[Drug-induced lung changes in rheumatology]
1Abteilung Pneumologie/Allergologie, Ruhrlandklinik, Essen.
Zeitschrift Fur Rheumatologie
|September 1, 1990
Summary
Certain medications used for rheumatologic disorders can cause lung damage. Early detection and drug withdrawal are crucial for patient recovery, though some drug-induced lung conditions have a poor prognosis.
Area of Science:
- Rheumatology
- Pulmonology
- Toxicology
Context:
- Rheumatologic disorders often require cytostatic and immunosuppressive agents.
- These medications can lead to lung parenchyma damage through toxic or immunologic mechanisms.
- Pulmonary manifestations of the underlying disease and infections are critical differential diagnoses.
Purpose:
- To review pulmonary side effects of common rheumatologic drugs including aspirin, gold, D-penicillamine, methotrexate, cyclophosphamide, and azathioprine.
- To highlight the importance of early diagnosis and drug withdrawal for potential patient recovery.
- To discuss diagnostic methods such as clinical, histological, and cytologic findings, including bronchoalveolar lavage.
Summary:
- Pulmonary side effects from these drugs are rare but can be severe, with a poor prognosis in cases of D-penicillamine or cyclophosphamide-induced pneumonitis (40-50% mortality).
- Symptoms include cough, dyspnea, and fever, with pulmonary function tests showing restriction and impaired diffusion.
- Bronchoalveolar lavage frequently reveals increased lymphocytes and a decreased CD4/CD8 ratio, aiding in excluding infections or underlying disease manifestations.
Impact:
- Emphasizes the need for vigilant monitoring of patients on immunosuppressive therapy for rheumatologic conditions.
- Early diagnosis and intervention can significantly improve outcomes for drug-induced lung injury.
- Provides a concise overview of diagnostic approaches and prognostic factors for pulmonary complications in rheumatology patients.